Signals
14AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
Heart failure with reduced ejection fraction therapy moves beyond four-pillar standard
Vericiguat addition, mechanism-targeted programs, and emerging genetically-defined HFrEF approaches are reshaping the post-four-pillar landscape.
Chronic kidney disease therapy options widen in non-diabetic populations
Finerenone in non-diabetic CKD, SGLT2 expansion past diabetes, and novel mechanism programs are restructuring CKD management beyond the diabetic kidney disease frame.
Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
Apolipoprotein C3-targeted therapy expands lipid management
ApoC3-targeted programs are widening the triglyceride-lowering toolset and entering routine lipid practice.
ATTR amyloidosis silencer therapy uptake is transforming a previously underdiagnosed condition
Transthyretin amyloid cardiomyopathy (ATTR-CM) was historically underdiagnosed and undertreated. Approved silencer therapies (siRNA, ASO) and TTR stabilisers have moved the field rapidly, and the diagnostic-pathway access remains the rate-limit on commercial uptake.
Hypertension treatment intensification gap remains the underdeveloped commercial opportunity
Real-world hypertension control rates across major markets remain substantially below guideline targets, with the treatment-intensification gap (patients on suboptimal regimens not advanced to combination or specialist therapy) as the principal driver. The commercial opportunity in closing this gap is large and is being addressed by combination-therapy programs and by emerging novel mechanisms.
GLP-1 supply normalisation is shifting the prescribing decision back to clinical fit
Manufacturing capacity for the GLP-1 class has substantially normalised after two years of supply constraint. The prescribing decision is moving back from availability-driven to clinical-fit-driven, and the commercial dynamics are shifting accordingly.
Finerenone CKD uptake reveals the cardio-renal-metabolic prescribing gap
Real-world finerenone uptake in chronic kidney disease patients with type 2 diabetes has been slower than the pivotal trial benefit profile would predict. The drivers are specialist coordination across cardiology, nephrology and endocrinology, and the operational complexity of integrating finerenone into existing regimens.
GLP-1 supply is normalising; access still depends on indication
Manufacturing capacity expansion has eased the chronic supply shortfall that defined 2023-24, but reimbursement variation by indication - obesity vs diabetes vs cardiovascular risk reduction - continues to define who can actually start therapy.
Snapshots
6Cardiac amyloidosis therapy reference (2026)
Reference snapshot of cardiac amyloidosis therapy across AL and ATTR types.
Lipid management therapy reference (2026)
Reference snapshot of lipid management therapy across foundational, add-on, and emerging tiers.
HFrEF therapy reference (2026)
Reference snapshot of HFrEF therapy across the four-pillar standard, additional approved options, and emerging mechanism classes.
Type 1 diabetes therapy reference (2026)
Reference snapshot of T1D therapy across insulin delivery, disease modification, and beta-cell replacement.
ATTR cardiomyopathy treatment landscape, 2026 mid-year reference
Reference layout of the ATTR cardiomyopathy treatment landscape as of mid-2026: TTR stabilisers, TTR silencers, the diagnostic-pathway infrastructure, and the live commercial questions including diagnostic-pathway expansion and combination therapy.
Obesity drug pipeline, 2026 mid-year reference
Reference layout of the obesity drug pipeline as of mid-2026: approved mechanisms, late-stage assets, the dual and triple agonist class, and the live commercial questions including manufacturing capacity, cardiovascular outcomes, and the indication-by-indication coverage frame.
Explained
6What is AL amyloidosis?
Plain-language primer on AL amyloidosis, why early diagnosis matters so much, and how modern therapy works.
PCSK9 inhibitors and modern lipid therapy explained
Plain-language primer on PCSK9 and the modern range of lipid-lowering options.
What is heart failure?
Plain-language primer on heart failure, why the modern therapy is built around four foundational classes, and what is changing.
What is type 1 diabetes?
Plain-language primer on type 1 diabetes, what is changing, and how modern therapy works.
How obesity coverage frames are diverging between cardiovascular-prevention and obesity-only indications
GLP-1 obesity therapy coverage is bifurcating across markets between cardiovascular-prevention indication framing and obesity-only indication framing. The differences in coverage breadth, prior-authorisation criteria, and prescriber pathway are material and are reshaping commercial planning across the class.
Why HFpEF is the chapter cardiology has been waiting to write
Heart failure with preserved ejection fraction was a diagnostic and therapeutic puzzle for thirty years. The arrival of SGLT2 inhibitors with HFpEF outcome benefit, combined with a more nuanced phenotype framework and the GLP-1 obesity-HFpEF subgroup data, has turned a disease without a treatment into a disease with a small but growing set of evidence-based options.